ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma

Abstract

• This ESMO Clinical Practice Guideline eUpdate addresses developments in first-line therapy in advanced urothelial carcinoma. • Enfortumab vedotin–pembrolizumab (EV–P) is the new standard of care in first-line advanced urothelial carcinoma. • Nivolumab–cisplatin–gemcitabine or platinum-based ChT and maintenance avelumab are alternatives if EV–P is not possible.